CAMP4 Therapeutics Corporation announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to its Board of Directors on March 18, 2025. These additions are expected to provide significant strategic insights as the company advances its clinical and preclinical programs.
Dr. Williams brings over 30 years of biopharma industry experience, having contributed to the development of several transformative drugs and held leadership roles at companies such as Biogen, ZymoGenetics, Amgen, and Immunex. His expertise spans critical aspects of R&D and drug development.
Dr. Stewart has extensive clinical development experience, including serving as Chief Medical Officer at Rhythm Pharmaceuticals and Head of R&D at Novelion Therapeutics, as well as corporate Chief Medical Officer at GlaxoSmithKline. His background includes leading studies across all stages and playing a key role in the successful registration and launch of multiple therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.